dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Hauser, Stephen L. |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Craveiro, Licinio |
dc.contributor.author | Chognot, Cathy |
dc.contributor.author | Hughes, Richard |
dc.contributor.author | Kappos, Ludwig |
dc.date.accessioned | 2022-07-18T12:37:26Z |
dc.date.available | 2022-07-18T12:37:26Z |
dc.date.issued | 2021-10-19 |
dc.identifier.citation | Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, et al. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 2021 Oct 19;97(16):e1546–59. |
dc.identifier.issn | 1526-632X |
dc.identifier.uri | https://hdl.handle.net/11351/7792 |
dc.description | Esclerosi múltiple; Seguretat del pacient; Atenció mèdica |
dc.description.sponsorship | This work was supported by financial support from F. Hoffmann-La Roche Ltd, Basel, Switzerland, for the study and publication of the manuscript. |
dc.language.iso | eng |
dc.publisher | Lippincott Williams & Wilkins |
dc.relation.ispartofseries | Neurology;97(16) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Medicaments - Efectes secundaris |
dc.subject | Anticossos monoclonals |
dc.subject.mesh | Multiple Sclerosis, Relapsing-Remitting |
dc.subject.mesh | /drug therapy |
dc.title | Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/WNL.0000000000012700 |
dc.subject.decs | esclerosis múltiple recurrente-remitente |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1212/WNL.0000000000012700 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Hauser SL] Department of Neurology, University of California, San Francisco. [Kappos L] Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Switzerland. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Craveiro L, Chognot C, Hughes R] F. Hoffmann-La Roche Ltd., Basel, Switzerland |
dc.identifier.pmid | 34475123 |
dc.identifier.wos | 000708601400017 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |